Anuh Pharma Limited has informed the Exchange regarding 'Anuh Pharma Limited has informed the Exchange regarding intimation for re-appointment of directors retiring by rotation'.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 6.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anuh Pharma reported FY2025-26 revenue of Rs. 7,717 lakh (up 16.6% from Rs. 6,615 lakh in prior year) and PAT of Rs. 410 lakh (up 9.2% from Rs. 474 lakh). EBITDA margin compressed to 8.56% from 10.64% a year earlier. The company declared a dividend of Rs. 1.50 per share (30% payout on face value Rs. 5) subject to shareholder approval at the AGM on 12th August 2026. The board re-appointed two directors (Mr. Bipin Shah and Mr. Arun Todarwal) retiring by rotation. Nine promoter group shareholders holding ~0.95% equity have sought re-classification to public category. Statutory auditors issued an unmodified opinion. Operating cash flow turned negative at Rs. 301 lakh vs Rs. 3,712 lakh in prior year, driven by a near doubling of inventory to Rs. 14,776 lakh. The company has zero borrowings. Bonus shares (1:1) were issued in July 2025.
Revenue grew solidly but margin compression and negative operating cash flow are concerns — investors should monitor working capital management. The dividend and clean audit provide support. Promoter re-classification is minor (under 1% of shares).